Related Experiment Video

Updated: May 24, 2026

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

Lower tissue factor inhibition in patients with ST segment elevation than in patients with non ST elevation acute

Jaume Figueras1, Jasone Monasterio, Rosa M Lidón

  • 1Unitat Coronaria, Àrea del Cor, Hospital Universitari Vall d'Hebron, Barcelona, Spain. 5751jfb@comb.es

Thrombosis Research
|March 20, 2012
PubMed

Insights

ST elevation myocardial infarction (STEMI) patients have lower tissue factor inhibition and greater endothelial dysfunction, contributing to more severe coronary thrombosis. These differences are primarily observed during the acute phase of the condition.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Thrombosis Research

Background:

  • Mechanisms differentiating coronary thrombosis in STEMI and non-STEMI patients are not well understood.
  • A hypothesis suggests STEMI patients may have reduced tissue factor plasma inhibition, leading to persistent coronary occlusion.

Purpose of the Study:

  • To investigate differences in coagulation and endothelial dysfunction markers between STEMI and non-STEMI patients.
  • To explore the role of tissue factor pathway inhibitor (TFPI) in the pathophysiology of STEMI.

Main Methods:

  • Measured total and free tissue factor plasma inhibitor (t-TFPI, f-TFPI), thrombin-antithrombin complex (TAT), PAI-1, von Willebrand factor (vWF), fibrinogen, and CRP in STEMI and non-STEMI patients.
  • Assessed these markers on admission and at 3 and 6 months post-event.

Main Results:

  • STEMI patients exhibited lower admission levels of t-TFPI, f-TFPI, and fibrinogen, with higher vWF levels compared to non-STEMI patients.
  • Coagulation markers (vWF, t-TFPI, f-TFPI, TAT) and CRP levels normalized or declined significantly by 3 and 6 months in both groups.
  • Admission coagulation parameters did not correlate with long-term cardiac mortality, MI, or stroke rates.

Conclusions:

  • Lower tissue factor inhibition and increased endothelial dysfunction in STEMI patients likely contribute to enhanced thrombosis at the culprit lesion and adjacent plaques.
  • These pro-thrombotic conditions appear to be specific to the acute phase of STEMI.
Abstract

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...